Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Zai Lab Limited

< Previous 1 2 3 4 Next >
News headline image
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Participation in May and June Investor Conferences
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Participation in March Investor Conference
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Participation in January Investor Conference
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
News headline image
Zai Lab Announces Participation in November Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
News headline image
Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
News headline image
Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
News headline image
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
News headline image
Zai Lab Announces Participation in September Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
News headline image
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
News headline image
Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.